Cargando…
Anti-tumor efficacy of CKD-516 in combination with radiation in xenograft mouse model of lung squamous cell carcinoma
BACKGROUND: Hypoxic tumors are known to be highly resistant to radiotherapy and cause poor prognosis in non-small cell lung cancer (NSCLC) patients. CKD-516, a novel vascular disrupting agent (VDA), mainly affects blood vessels in the central area of the tumor and blocks tubulin polymerization, ther...
Autores principales: | Kim, Min-Young, Shin, Jung-Young, Kim, Jeong-Oh, Son, Kyoung-Hwa, Kim, Yeon Sil, Jung, Chan Kwon, Kang, Jin-Hyoung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607852/ https://www.ncbi.nlm.nih.gov/pubmed/33143663 http://dx.doi.org/10.1186/s12885-020-07566-x |
Ejemplares similares
-
Phase I and pharmacokinetic study of the vascular‐disrupting agent CKD‐516 (NOV120401) in patients with refractory solid tumors
por: Kim, Hark Kyun, et al.
Publicado: (2020) -
Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors
por: Oh, Do-Youn, et al.
Publicado: (2016) -
Early quantification of the therapeutic efficacy of the vascular
disrupting agent, CKD-516, using dynamic contrast-enhanced ultrasonography in
rabbit VX2 liver tumors
por: Joo, Ijin, et al.
Publicado: (2014) -
Quantitative Estimation of the Equivalent Radiation Dose Escalation using Radiofrequency Hyperthermia in Mouse Xenograft Models of Human Lung Cancer
por: Prasad, Bibin, et al.
Publicado: (2019) -
Relationship between volume status and possibility of pulmonary hypertension in dialysis naive CKD5 patients
por: Han, Byoung-Geun, et al.
Publicado: (2019)